Ferma Congress

APRIL 2025

ZOOMRX

Our conference coverage is robust and flexible, we enable client teams to amplify their conference CI with high-velocity, hyper-personalized insights

100+
CONFERENCES
for
25+
CLIENTS
...SINCE 2020

PROVEN FRAMEWORK

A well-developed approach, where coverage is tailored for pre-, peri-, and post-conference needs

AI-ENHANCED MODULES

Instant summaries for any presentation at a conference

Complex custom analyses, spanning across multiple conference datasets, generated near-instantly

COMPREHENSIVE & ADAPTABLE APPROACH

Planning for session coverage (in-person and virtually) spanning Client priorities and competitor of interest

Your *One-Stop* Conference Intelligence Platform

CUSTOM PRIORITIZED PLANNERS IN 24 HOURS

for each participating teams across multiple disease areas prioritized based on their competitive landscape, all accessible on the Ferma portal



AUTO-GENERATED ONE-CLICK SUMMARIES

available on the Ferma portal within 4 hours of the session; designed to deliver quick, detailed snapshots of any conference presentation. These can be downloaded as PowerPoint slides and plugged into your workflows instantly.

FERMA INSIGHTS

an AI-Driven Interactive Module that generates real-time, tailored insights to your KBQs (or any other question), enabling swift responses to emerging data, competitor actions, and market trends.

Conference Coverage *Workflow*

- Understand competitive landscape for each team
- Align on keywords & phrases, priority competitors
- Collect internal Abstracts
- Discuss any other key business questions

ABSTRACTS RELEASED

- Abstracts populated within 6 hours
- In less than 12 hours, automated prioritization of abstracts available
- Within 24-36 hours, manually reviewed and QC'ed planner is ready

PRE-CONFERENCE

- As time permits, continue prioritization and refinement of sessions and abstracts
- Option for pre-conference report with key themes, prioritization stats and social traction data with tweets, news, & PRs



PERI-CONFERENCE

- Priority session updates for High Priorities in less than 4 hours
- Photos, videos, posters, and decks (as available) uploaded by end of day along with a report of daily highlights
- AI Generated One-click Summaries available along with the content



POST-CONFERENCE

- Automated updates to session overviews (incl. transcripts as available) within 24-48 hours
- Full report available 1 week post conference

One Stop *Portal*



One Click *Summaries*

- Conferences today feature thousands of sessions running simultaneously, making it challenging to gather key data efficiently.
- With One-Click Summaries, effortlessly download a single-slide summary of ANY presentation.
- Each PowerPoint slide is pre-formatted to integrate seamlessly into your reports—just add your custom implications.



Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI)

Amanda Jones et al.; P7-040

Product	Company	Indication	Phase/Trial ID
AXS-05	Axsome Therapeutics	Major Depressive Disorder	Phase 3 (NCT04019704)

Background

Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion), an oral N-methyl-D-aspartate (NMDA) receptor antagonist and σ1 receptor agonist, in the treatment of major depressive disorder (MDD).

Study Design

- This double-blind, phase 3 trial, was conducted between June 2019 and December 2019
- Patients with a DSM-5 diagnosis of MDD were randomized in a 1:1 ratio to receive dextromethorphan-bupropion (45 mg-105 mg tablet) or placebo, orally (once daily for days 1–3, twice daily thereafter) for 6 weeks
- The primary endpoint was the change from baseline to week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score

Results

- A total of 327 patients were randomized: 163 patients to dextromethorphan-bupropion and 164 patients to placebo
- Dextromethorphan-bupropion was superior to placebo for MADRS improvement at all time points including week 1 (P = .007) and week 2 (P < .001)
- Remission was achieved by 39.5% of patients with dextromethorphan-bupropion versus 17.3% with placebo (treatment difference, 22.2; 95% CI, 11.7 to 32.7; P < .001), and clinical response by 54.0% versus 34.0%, respectively
- Results for most secondary endpoints were significantly better with dextromethorphan-bupropion than with placebo at almost all time points
- Common adverse events in the dextromethorphan-bupropion group were dizziness, nausea, headache, somnolence, and dry mouth
- Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or increased sexual dysfunction

Conclusion

- In this phase 3 trial in patients with MDD, treatment with dextromethorphan-bupropion (AXS-05) resulted in significant improvements in depressive symptoms compared to placebo starting 1 week after treatment initiation and was generally well tolerated

Supporting Images

Figure 2. MADRS Total Scores, Remission, and Clinical Response in a Phase 3 Trial of AXS-05 (Dextromethorphan-Bupropion) for Major Depressive Disorder (mITT)

A. MADRS Total Scores Over Time[a]

Implications

- Study demonstrated that treatment with dextromethorphan-bupropion (AXS-05) resulted in clinically meaningful and statistically significant improvements in depressive symptoms compared to placebo starting at week 1 in patients with MDD and was well tolerated
- The efficacy of dextromethorphan-bupropion was supported by significant improvements compared to placebo on multiple clinically relevant endpoints across symptom-specific and global measures, demonstrating internal consistency of the study results

Cut through the clutter

LET ONE-CLICK SUMMARIES DO THE WORK

One Click *Summaries*

- Empower your decisions with Ferma Insights, an AI-driven module designed to deliver instant, customized answers to your KBQs. Stay ahead by responding swiftly to new data, competitor moves, and market dynamics.
- Effortlessly analyze conference data with automated insights, eliminating manual effort.
- Export results directly into Excel, PowerPoint, or Word, seamlessly integrating into your workflow.



Focus on Action

LET FERMA HANDLE THE HEAVY LIFTING

Get in touch

info@zoomrx.com